期刊
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
卷 15, 期 -, 页码 3-10出版社
WILEY
DOI: 10.1111/ajco.13289
关键词
immuno-oncology; renal cell carcinoma; VEGF tyrosine kinase inhibitors
类别
资金
- Novartis Pharmaceuticals Australia
Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据